Maintenance therapy for metastatic colorectal cancer.

نویسنده

  • Fortunato Ciardiello
چکیده

1444 www.thelancet.com/oncology Vol 16 November 2015 7 Blakely T, Shaw C, Atkinson J, Cunningham R, Sarfati D. Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981–1986 to 2001–2004. Cancer Causes Control 2011; 22: 1307–18. 8 Paltoo DN, Chu KC. Patterns in cancer incidence among American Indians/ Alaska Natives, United States, 1992–1999. Public Health Rep 2004; 119: 443–51. 9 Soeberg M, Blakely T, Sarfati D, et al. Cancer trends: trends in survival by ethnic and socioeconomic group, New Zealand 1991–2004. Wellington: University of Otago and Ministry of Health, 2012. 10 Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3–27. 11 Sheppard AJ, Chiarelli AM, Marrett LD, Nishri ED, Trudeau ME. Stage at diagnosis and comorbidity infl uence breast cancer survival in First Nations women in Ontario, Canada. Cancer Epidemiol Biomarkers Prev 2011; 20: 2160–67. 12 Valery PC, Coory M, Stirling J, Green AC. Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet 2006; 367: 1842–48. 13 United Nations Permanent Forum on Indigenous Peoples. State of the world’s indigenous peoples. Volume Two: Access to Health Services. http://undesadspd.org/IndigenousPeoples/LibraryDocuments.aspx (accessed Aug 25, 2015).

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Disseminated thoracoabdominal splenosis mimicking metastatic disease: A case of colorectal cancer

Here, we describe a patient with a history of colorectal cancer in whom 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) was performed for the evaluation of response to therapy. [18F]FDG PET/CT showed a small residual disease in the rectum. In addition, multiple metabolically inactive soft tissue densities were d...

متن کامل

Expert consensus on maintenance treatment for metastatic colorectal cancer in China

The impact of maintenance therapy on progression-free survival and overall survival as well as quality of life of Chinese patients with metastatic colorectal cancer has long been under discussion. Recently, some phase III clinical trials have revealed that maintenance therapy can significantly prolong the progression-free survival while maintain an acceptable safety profile. Based on this evide...

متن کامل

Who will benefit more from maintenance therapy of metastatic colorectal cancer?

Whether there is a difference in the efficacy of maintenance treatment for metastatic colorectal cancer (mCRC) between patients who achieve complete response (CR)/partial response (PR) and those with stable disease (SD) after induction treatment is controversial. PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, a...

متن کامل

Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study

Background MGN1703, a potent immunomodulatory Toll-like receptor 9 (TLR-9) agonist, was compared to placebo in the previous double-blind, randomized Phase II IMPACT study. The drug was given as switch maintenance in 59 patients with metastatic colorectal cancer (mCRC) not progressing after 4.5 to 6 months of induction chemotherapy +/bevacizumab, considered the most appropriate setting for an ag...

متن کامل

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT

27(5): 672–680. 19. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842–1847. 20. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observationa...

متن کامل

Use of Bevacizumab in Metastatic Colorectal Cancer

Colorectal cancer is one of the most common cancers worldwide, and although associated mortality rates in South American countries are generally among the lowest in the world, they are on the rise. The prognosis of patients diagnosed with metastatic colorectal cancer has improved markedly over the last 12 years, increasing from 5 months with best supportive care to almost 2 years with combinati...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical advances in hematology & oncology : H&O

دوره 12 6  شماره 

صفحات  -

تاریخ انتشار 2014